Radionuclide Prostate Membrane Antigen 225Ac-J591 & 177Lu-PSMA I&T

Scott T Tagawa, MD, MS, FASCO, FACP – Weill Cornell

This study explores the use of a combination therapy, involving both alpha and beta radioligands, for prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) in patients with metastatic castration-resistant prostate cancer. The preliminary phase I results indicate the feasibility and safety of combining the alpha-radiolabeled antibody 225Ac-J591 with the beta-radioligand 177Lu-PSMA I&T. Promising efficacy outcomes, such as PSA decline and favorable circulating tumor cell changes, are observed, and further evaluation will be conducted in the phase II portion of the study.